ANI Pharmaceuticals Financial Statements (ANIP)
|
|
Report date
|
|
|
27.02.2020 |
11.03.2021 |
15.03.2022 |
09.03.2023 |
29.02.2024 |
|
08.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
206.5 |
208.5 |
216.1 |
316.4 |
486.8 |
|
555.5 |
Operating Income, bln rub |
|
|
16.4 |
-16.1 |
-32.5 |
-25.1 |
47.0 |
|
8.78 |
EBITDA, bln rub |
? |
|
60.7 |
29.1 |
-1.68 |
48.1 |
109.3 |
|
64.0 |
Net profit, bln rub |
? |
|
6.09 |
-22.5 |
-42.6 |
-47.9 |
18.8 |
|
-7.09 |
|
OCF, bln rub |
? |
|
45.6 |
15.3 |
3.32 |
-31.2 |
119.0 |
|
92.9 |
CAPEX, bln rub |
? |
|
27.5 |
68.3 |
23.6 |
16.5 |
18.5 |
|
22.8 |
FCF, bln rub |
? |
|
18.1 |
-53.1 |
-20.3 |
-47.7 |
100.4 |
|
88.1 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.190 |
1.63 |
1.63 |
|
1.63 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
8.65% |
|
-22.9% |
|
OPEX, bln rub |
|
|
127.0 |
136.9 |
143.7 |
203.3 |
196.0 |
|
341.8 |
Cost of production, bln rub |
|
|
63.2 |
87.2 |
100.6 |
138.8 |
181.5 |
|
267.9 |
R&D, bln rub |
|
|
19.8 |
16.0 |
11.4 |
22.3 |
34.3 |
|
37.8 |
Interest expenses, bln rub |
|
|
13.0 |
9.45 |
11.9 |
28.1 |
26.9 |
|
17.2 |
|
Assets, bln rub |
|
|
456.8 |
461.2 |
771.6 |
760.1 |
904.4 |
|
1 287 |
Net Assets, bln rub |
? |
|
212.8 |
195.7 |
358.7 |
338.5 |
432.7 |
|
430.8 |
Debt, bln rub |
|
|
185.7 |
185.7 |
287.4 |
286.5 |
285.7 |
|
625.4 |
Cash, bln rub |
|
|
62.3 |
7.86 |
100.3 |
48.2 |
221.1 |
|
145.0 |
Net debt, bln rub |
|
|
123.4 |
177.8 |
187.1 |
238.3 |
64.5 |
|
480.4 |
|
Ordinary share price, rub |
|
|
61.7 |
29.0 |
46.1 |
40.2 |
55.1 |
|
62.6 |
Number of ordinary shares, mln |
|
|
11.8 |
12.0 |
12.6 |
16.3 |
18.0 |
|
19.4 |
|
Market cap, bln rub |
|
|
730 |
347 |
580 |
654 |
993 |
|
1 214 |
EV, bln rub |
? |
|
854 |
525 |
767 |
892 |
1 057 |
|
1 694 |
Book value, bln rub |
|
|
29 |
4 |
37 |
59 |
196 |
|
-199 |
|
EPS, rub |
? |
|
0.51 |
-1.88 |
-3.38 |
-2.95 |
1.04 |
|
-0.37 |
FCF/share, rub |
|
|
1.53 |
-4.43 |
-1.61 |
-2.93 |
5.58 |
|
4.54 |
BV/share, rub |
|
|
2.43 |
0.30 |
2.92 |
3.61 |
10.9 |
|
-10.3 |
|
EBITDA margin, % |
? |
|
29.4% |
13.9% |
-0.78% |
15.2% |
22.5% |
|
11.5% |
Net margin, % |
? |
|
2.95% |
-10.8% |
-19.7% |
-15.1% |
3.86% |
|
-1.28% |
FCF yield, % |
? |
|
2.48% |
-15.3% |
-3.50% |
-7.29% |
10.1% |
|
7.26% |
ROE, % |
? |
|
2.86% |
-11.5% |
-11.9% |
-14.1% |
4.34% |
|
-1.65% |
ROA, % |
? |
|
1.33% |
-4.89% |
-5.52% |
-6.30% |
2.08% |
|
-0.55% |
|
P/E |
? |
|
119.8 |
-15.4 |
-13.6 |
-13.7 |
52.9 |
|
-171.2 |
P/FCF |
|
|
40.4 |
-6.55 |
-28.6 |
-13.7 |
9.88 |
|
13.8 |
P/S |
? |
|
3.54 |
1.67 |
2.69 |
2.07 |
2.04 |
|
2.19 |
P/BV |
? |
|
25.3 |
96.3 |
15.8 |
11.1 |
5.08 |
|
-6.09 |
EV/EBITDA |
? |
|
14.1 |
18.1 |
-455.8 |
18.6 |
9.67 |
|
26.5 |
Debt/EBITDA |
|
|
2.03 |
6.12 |
-111.1 |
4.96 |
0.59 |
|
7.51 |
|
R&D/CAPEX, % |
|
|
71.9% |
23.4% |
48.1% |
135.6% |
185.2% |
|
165.5% |
|
CAPEX/Revenue, % |
|
|
13.3% |
32.8% |
10.9% |
5.20% |
3.80% |
|
4.11% |
|
ANI Pharmaceuticals shareholders |